Lixisenatide produces antibodies in 56 to 70% of users but injection site reactions in only 3.9%
An overview of the European Journal of Clinical Pharmacology, states that intravenous glutathione has been safely applied in medical practice over decades
Emerging reviews of the GLP-1 market anticipate continued demand, pipeline diversification, and health-system impact as agents move earlier in care pathways, reinforcing the case for meaningful market expansion through 2026-2028
Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which means it mimics the action of these incretin hormones to enhance insulin secretion, suppress glucagon release, and slow gastric emptying
doi:10.1080/00365513.2020.1804610 Kanth VV, Golla JP, Sastry BK, et al
Bu nedenle slfonilrelerin gerekten kardiyak iskemiye yatknlk yaratt ispatlanmamtr